T. Rowe Price Associates
WHWK

T. Rowe Price Associates’s Whitehawk Therapeutics WHWK Stock Holding History

T. Rowe Price Associates’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$122K Buy
+26,609
New +$111K ﹤0.01% 3116
2024
Q2 		– Sell
-10,692
Closed -$26K – 3048
2024
Q1 		$26K Hold
10,692
– – ﹤0.01% 2923
2023
Q4 		$22K Sell
10,692
-200,000
-95% -$839K ﹤0.01% 2870
2023
Q3 		$1.02M Sell
210,692
-17,705
-8% -$103K ﹤0.01% 1787
2023
Q2 		$1.56M Sell
228,397
-9,332
-4% -$72.5K ﹤0.01% 1579
2023
Q1 		$1.72M Sell
237,729
-7,514
-3% -$80.3K ﹤0.01% 1515
2022
Q4 		$3.15M Sell
245,243
-6,036
-2% -$78.8K ﹤0.01% 1300
2022
Q3 		$3.55M Buy
251,279
+4,041
+2% +$53.1K ﹤0.01% 1268
2022
Q2 		$3.05M Sell
247,238
-188,713
-43% -$2.8M ﹤0.01% 1503
2022
Q1 		$7.4M Sell
435,951
-72,941
-14% -$1.4M ﹤0.01% 1412
2021
Q4 		$12.3M Buy
508,892
+43,293
+9% +$1.09M ﹤0.01% 1378
2021
Q3 		$13M Buy
465,599
+448,686
+2,653% +$13.7M ﹤0.01% 1390
2021
Q2 		$429K Hold
16,913
– – ﹤0.01% 2456
2021
Q1 		$327K Buy
+16,913
New +$389K ﹤0.01% 2533

Other funds holding WHWK

YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates's WHWK Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in Whitehawk Therapeutics (WHWK) in Q2 2026: 26,609 shares worth $122K. The stake represents ﹤0.01% of the portfolio and ranks #3116 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in WHWK as recently as Q1 2024.

T. Rowe Price Associates first reported a position in WHWK in Q1 2021 and has held it in 14 quarters since. The position peaked at $13M in Q3 2021. 77 funds tracked by Wall St. Rank hold WHWK as of Q2 2026.

  • T. Rowe Price Associates held 26,609 shares of Whitehawk Therapeutics worth $122K as of Q2 2026.
  • Whitehawk Therapeutics was a new T. Rowe Price Associates position in Q2 2026.
  • Whitehawk Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3116 holding.
  • T. Rowe Price Associates first reported a position in Whitehawk Therapeutics in Q1 2021 and has held it in 14 quarters since.
  • T. Rowe Price Associates's Whitehawk Therapeutics position peaked at $13M in Q3 2021.
  • 77 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.